A Study in Healthy Volunteers and Patients With Chronic Hepatitis B
Completed
Assembly Biosciences
Phase 1
This two-part, Phase 1 protocol will be the first clinical study of ABI-H0731. Part I will be
a Phase 1a dose-ranging assessment of ABI-H0731 in healthy adult volunteers. If the
dose-related safety, tolerability and pharmacokinetics (PK) of ABI-H0731 in human volunteers
are deemed satisfactory, then the study will advance to Part II, a Phase 1b dose-ranging
assessment of ABI-H0731 in non-cirrhotic, CHB patients.
Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B
Completed
Assembly Biosciences
Phase 1/Phase 2
The purpose of this protocol is to obtain pharmacodynamic and pharmacokinetic data on
ABI-H0731 and to provide the opportunity for preliminary evaluation of combination therapy of
ABI-H0731 with currently approved antiviral treatment for chronic hepatitis B.
A Study Evaluating ABI-H0731 as Adjunctive Therapy in Participants With Chronic Hepatitis B Infection
Completed
Assembly Biosciences
Phase 2
The purpose of this study is to determine if ABI-H0731 given in combination with a standard
of care (SOC) hepatitis B virus (HBV) nucleos(t)ide reverse transcriptase inhibitor (NUC)
medication is safe and effective in participants with chronic hepatitis B virus infection
(cHBV).
A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)
Completed
Assembly Biosciences
Phase 2
The purpose of this study is to determine if ABI-H0731 given in combination with a standard
of care (SOC) entecavir (ETV) is safe and effective in participants with chronic hepatitis B
infection (cHBV)
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
